148 related articles for article (PubMed ID: 38581590)
1. Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study.
Hietikko R; Mirtti T; Kilpeläinen TP; Tolonen T; Räisänen-Sokolowski A; Nordling S; Hannus J; Laurila M; Taari K; Tammela TLJ; Autio R; Natunen K; Auvinen A; Rannikko A
World J Urol; 2024 Apr; 42(1):217. PubMed ID: 38581590
[TBL] [Abstract][Full Text] [Related]
2. Expected impact of MRI-related interreader variability on ProScreen prostate cancer screening trial: a pre-trial validation study.
Hietikko R; Kilpeläinen TP; Kenttämies A; Ronkainen J; Ijäs K; Lind K; Marjasuo S; Oksala J; Oksanen O; Saarinen T; Savolainen R; Taari K; Tammela TLJ; Mirtti T; Natunen K; Auvinen A; Rannikko A
Cancer Imaging; 2020 Oct; 20(1):72. PubMed ID: 33036660
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
Lim CS; Abreu-Gomez J; Carrion I; Schieda N
AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
[No Abstract] [Full Text] [Related]
4. [Analysis of the relationship between PI-RADS scores and the pathological results of targeted biopsy based on MRI].
Wang YM; Shang JW; Dong L; Liang LH; Zhao RZ; Liang C; Wang SQ; Xia W; Cheng G; Hua LX
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):942-947. PubMed ID: 37968079
[No Abstract] [Full Text] [Related]
5. The combined role of MRI prostate and prostate health index in improving detection of significant prostate cancer in a screening population of Chinese men.
Chiu PK; Lam TY; Ng CF; Teoh JY; Cho CC; Hung HY; Hong C; Roobol MJ; Chu WC; Wong SY; Sung JJ
Asian J Androl; 2023 Nov; 25(6):674-679. PubMed ID: 37534902
[TBL] [Abstract][Full Text] [Related]
6. Systematic versus Targeted Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy among Men with Visible Lesions.
Patel HD; Koehne EL; Shea SM; Fang AM; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
J Urol; 2022 Jan; 207(1):108-117. PubMed ID: 34428091
[TBL] [Abstract][Full Text] [Related]
7. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G
BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
[TBL] [Abstract][Full Text] [Related]
8. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
[TBL] [Abstract][Full Text] [Related]
9. Automated deep-learning system for Gleason grading of prostate cancer using biopsies: a diagnostic study.
Bulten W; Pinckaers H; van Boven H; Vink R; de Bel T; van Ginneken B; van der Laak J; Hulsbergen-van de Kaa C; Litjens G
Lancet Oncol; 2020 Feb; 21(2):233-241. PubMed ID: 31926805
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
11. Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study.
Ström P; Kartasalo K; Olsson H; Solorzano L; Delahunt B; Berney DM; Bostwick DG; Evans AJ; Grignon DJ; Humphrey PA; Iczkowski KA; Kench JG; Kristiansen G; van der Kwast TH; Leite KRM; McKenney JK; Oxley J; Pan CC; Samaratunga H; Srigley JR; Takahashi H; Tsuzuki T; Varma M; Zhou M; Lindberg J; Lindskog C; Ruusuvuori P; Wählby C; Grönberg H; Rantalainen M; Egevad L; Eklund M
Lancet Oncol; 2020 Feb; 21(2):222-232. PubMed ID: 31926806
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the optimal strategy in men with a single unilateral suspicious lesion on MRI undergoing transperineal MRI/ultrasound fusion prostate biopsy.
Yusim I; Mazor E; Frumkin E; Jabareen M; Hefer B; Elsaraya N; Li S; Rouvinov K; Novack V; Mabjeesh NJ
Prostate; 2023 Sep; 83(13):1255-1262. PubMed ID: 37263774
[TBL] [Abstract][Full Text] [Related]
13. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial.
Tonttila PP; Lantto J; Pääkkö E; Piippo U; Kauppila S; Lammentausta E; Ohtonen P; Vaarala MH
Eur Urol; 2016 Mar; 69(3):419-25. PubMed ID: 26033153
[TBL] [Abstract][Full Text] [Related]
14. Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies.
Martin DT; Ghabili K; Levi A; Humphrey PA; Sprenkle PC
Urology; 2019 Mar; 125():64-72. PubMed ID: 30552940
[TBL] [Abstract][Full Text] [Related]
15. Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial.
Klotz L; Loblaw A; Sugar L; Moussa M; Berman DM; Van der Kwast T; Vesprini D; Milot L; Kebabdjian M; Fleshner N; Ghai S; Chin J; Pond GR; Haider M
Eur Urol; 2019 Feb; 75(2):300-309. PubMed ID: 30017404
[TBL] [Abstract][Full Text] [Related]
16. Additional value of magnetic resonance-targeted biopsies to standard transrectal ultrasound-guided biopsies for detection of clinically significant prostate cancer.
von Below C; Wassberg C; Norberg M; Tolf A; Kullberg J; Ladjevardi S; Häggman M; Bill Axelson A; Ahlström H
Scand J Urol; 2017 Apr; 51(2):107-113. PubMed ID: 28635568
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Multiparametric Magnetic Resonance Imaging-Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial.
Klotz L; Chin J; Black PC; Finelli A; Anidjar M; Bladou F; Mercado A; Levental M; Ghai S; Chang SD; Milot L; Patel C; Kassam Z; Moore C; Kasivisvanathan V; Loblaw A; Kebabdjian M; Earle CC; Pond GR; Haider MA
JAMA Oncol; 2021 Apr; 7(4):534-542. PubMed ID: 33538782
[TBL] [Abstract][Full Text] [Related]
18. A grading dilemma; Gleason scoring system: Are we sufficiently compatible? A multi center study.
Dere Y; Çelik ÖI; Çelik SY; Ekmekçi S; Evcim G; Pehlivan F; Ağalar A; Deliktaş H; Çulhacı N
Indian J Pathol Microbiol; 2020 Feb; 63(Supplement):S25-S29. PubMed ID: 32108622
[TBL] [Abstract][Full Text] [Related]
19. Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer.
Jayadevan R; Felker ER; Kwan L; Barsa DE; Zhang H; Sisk AE; Delfin M; Marks LS
JAMA Netw Open; 2019 Sep; 2(9):e1911019. PubMed ID: 31509206
[TBL] [Abstract][Full Text] [Related]
20. MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: follow-up of a PRECISION trial-like retrospective cohort.
Luzzago S; de Cobelli O; Mistretta FA; Piccinelli ML; Lorusso V; Morelli M; Bianchi R; Catellani M; Cozzi G; Di Trapani E; Pricolo P; Alessi S; Ferro M; Marvaso G; Matei DV; Jereczek-Fossa BA; Petralia G; Musi G
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):406-413. PubMed ID: 32989259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
